Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Emergent BioSolutions Inc. (EBS)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
35.33+3.64 (+11.49%)
At close: 04:00PM EDT
36.00 +0.67 (+1.90%)
After hours: 07:59PM EDT
Advertisement
Sign in to post a message.
  • V
    Vlad
    The smallpox virus is sweeping across Europe, a new wake-up call for vaccine company growth
    Bullish
  • J
    Jad
    Why $EBS in best position on monkeypox:
    A) bought Sanofi smallpox vaccine
    https://t.co/M1L7YZDVgf
    B) bought smallpox antiviral off Chimerix
    https://t.co/dVUM8w5GAw
    C) Own VIGIV, a smallpox vaccination complication med
    D) Have long history with governments
  • B
    B
    Around 12% of the Float is shorted...
    Bullish
  • d
    dr
    Yahoo doesn't like the truth people.

    The version of the vaccine they purchased isn't even FDA approved and wont be delivered until 2023-24. They only just completed Phase 3. All about the optics. Total incompetence.
  • S
    SamHtwoP
    EBS is cornering the market on smallpox. Awesome , am eradicated disease that hasn’t infected anyone naturally since the early 1970’s. Good move (sarcasm). . More scare tactics by EBS on its way .
  • B
    Blockbuster
    (BIVI) MC $71 million // 3x Blockbusters in Pipeline targeting Alzheimer Disease (Phase 3 data in mid 2023) and Parkinsons Disease (Phase 2 data coming this quarter) Slide Presentation below =10 Bagger opp
    https://bioviepharma.com/wp-content/uploads/2022/04/BioVie-Company-Overview-2022-04-13.pdf

    #+#
  • c
    cosmicdust
    A North Carolina drug manufacturer will give a potentially life-saving medication to a 7-year-old boy whose case led thousands of people to apply pressure to the company.

    Josh Hardy, of Fredericksburg, Va., who is fighting an adenovirus infection after a bone marrow transplant, will get the experimental antiviral drug brincidofovir as the first patient in a new pilot study, according to the company, Chimerix, of Durham, N.C.

    This drug has much more potential than pox, potential gold mine.
    if you have mono, perhaps ebs can help.
  • S
    SamHtwoP
    EBS “ where quality counts” we will make your vaccine then coverup the destruction of 400 million doses . So sorry won’t happen again . Btw @ 20/ dose that ~ 8 billion in revenue lost by their clients . Ooopps . Call now we have manufacturing slots available .
  • S
    SamHtwoP
    Next up, US gov contracts for anthrax and small pox. The sales scare tactics of emergent with US gov are over. Gov contracts will be greatly reduced, put out to bid, the Emergent name is violently destroyed. Board and Execs should be already fired. Sell the assets, company is done , dumpster fire can't be put out.
  • d
    dr
    Great article in the Epoch Times detailing the same democrats who wrote the negative report on EBS have nothing to say about the millions in royalties Fauci and NIH collect. Conflict of interest?? Can't post the link cause Yahoo won't allow it - seems they only allow links from those on their payroll who advance their narrative.

    "Democrats Silent as Republicans Rip Into Secret Royalty Checks to Fauci, Hundreds of NIH Scientists"
  • c
    ctbnfo
    Ebs needs to court or merge with Nvax imo
  • Y
    Yo Dawg Investin
    Sold out of this last year. Management still dishing out their BS to their shareholders with their magical Guidance numbers?
    Neutral
  • d
    dr
    Other than the uncertainty surrounding the business with J&J, the numbers don't look bad. Considering this was a $70 stock before covid and J&J, there's got to be something else holding this down.
  • S
    SamHtwoP
    For the people who bought this today I’m pleading with you to seek mental health assistance . The whole executive team and most of the board should be terminated . “I’m sorry” doesn’t cut it with this .
  • S
    SamHtwoP
    Just want to point out that I predicted 100% accurately that this was a $30/stock ... at best. Go ahead search my posts. Company has no reputable cmo business and no pipeline.
  • d
    dr
    Seems the company lacks direction. Investing in a treatment for cyanide poisoning when there's already antidotes and treatments seems like a waste but I guess if BARDAs giving you free money you need to spend it on something. https://www.sciencedirect.com/topics/neuroscience/cyanide-poisoning
  • W
    WD85
    This will do fine.
    Most of the bad news is behind emergent
    Bullish
  • A
    Anonymous
    Emergent BioSolutions announces $250M share buyback program
    Nov. 11, 2021 4:23 PM ETEmergent BioSolutions Inc. (EBS)By: Dulan Lokuwithana, SA News Editor
    15 Million Doses Of Johnson & Johnson Vaccine Ruined At Baltimore Lab Mix-Up
    Tasos Katopodis/Getty Images News

    Emergent BioSolutions (NYSE:EBS) is trading ~4.4% higher after the company announced an authorization to repurchase up to $250M of the company’s common stock.
    Based on market conditions and other factors, the buybacks will be carried out from time to time on the open market and through privately negotiated transactions. The authorization expires on Nov. 11, 2022.
    CEO Robert G. Kramer stated that the decision to allow repurchases demonstrate the company’s financial position.
    “As part of a balanced capital management plan, we believe the company's stock can represent an attractive investment opportunity,” he added.
    The share repurchases are funded by cash on hand and operational cash flow. As of the end of Q3 2021, Emergent (EBS) recorded ~$404M in cash and equivalents, while its quarterly revenue contracted ~15% YoY to $329M.
    Read: 89bio EPS misses by $0.35
    Never miss the best stock ideas!
    Stock Ideas Newsletter
    260,905 subs.
    Recommended For You
Advertisement
Advertisement